SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
== Use as a biomarker == Dinosterol is used as a biomarker for organic matter derived from dinoflagellates in sediments and seawater. Biomarkers are organic compounds that are indicative of former life in sediments, seawater and oil. The presence of the saturated hydrocarbon counterpart, dinosterane, is used as evidence that some of the organic matter present in ancient sediments may have been derived from dinoflagellates.
As enzyme-catalysed reactions are saturable, their rate of catalysis does not show a linear response to increasing substrate. If the initial rate of the reaction is measured over a range of substrate concentrations (denoted as [S]), the initial reaction rate (
=== 1970s === Following Giant-Size X-Men, the X-Men comic was revived with issue #94 (August 1975), drawn by Cockrum and written by Chris Claremont. Wolverine is initially overshadowed by the other characters, although he creates tension in the team as he is attracted to Cyclops' girlfriend, Jean Grey. As the series progressed, Claremont considered dropping Wolverine from the comic; Cockrum's successor, artist John Byrne, championed the character, later explaining that as a Canadian himself he did not want to see the only Canadian character dropped. Byrne modeled his rendition of Wolverine on actor Paul D'Amato, who played Dr. Hook in the sports film Slap Shot (1977). Cockrum introduced another costume for Wolverine in the final issue of his run, but it was dropped at the start of Byrne's run because he found it difficult to draw. Wolverine was first drawn without his mask in X-Men #98 (April 1976); his distinctive hairstyle became one of his trademarks. The same issue also established that Wolverine's claws are an integrated part of his anatomy. X-Men #100 introduces the "fastball special", a combat maneuver in which the super-strong Colossus throws Wolverine at a distance as if he were a projectile weapon; this tactic recurs in many future battles. Stories of the late 1970s establish Wolverine's murky past and unstable nature, which he battles to keep in check. Wolverine's name was revealed as "Logan" in X-Men #103 (February 1977); Claremont drew inspiration from Canada's Mount Logan, liking "the idea [of] the tallest mountain being the name of the shortest character".
Sources: en.wikipedia.org
=== Building blocks for cell-adhesion === By looking at the genome of the Choanoflagellate, "Monosiga brevicollis", scientists have inferred that choanoflagellates play a key role in the development of multicellularity. Nicole King has done work looking at the genome of Monisiga brevicollis, and has found key protein domains that are shared between metazoans and choanoflagellates. These domains play a role in cell signalling and adhesion processes in metazoans. The finding that choanoflagellates also have these genes is an incredible discovery because it was previously thought that only metazoans had genes responsible for cell-cell communication and aggregation. This suggests that these domains play a key role in the origins of multicellularity since it ties a unicellular organism (choanoflagellates) to multicellular organisms (metazoans). It shows that the components required for multicellularity were present in the common ancestor between metazoans and choanoflagellates.
There are at least 45 precursor isotopes. In reactor analysis they are conventionally combined into six effective groups, each with an effective half-life (about 55, 22, 6, 2, 0.5, and 0.2 seconds) and an effective yield. The 55-second group is dominated by 87Br, the 22-second group by 88Br and 137I, and the shorter-lived groups have many contributors. The group parameters depend on the fuel isotope, since fission product yields vary with the fissile material. An eight-group structure has also been defined, which uses the same set of half-lives for all fissioning systems, with the three longest-lived groups corresponding to the three dominant long-lived precursors 87Br, 137I and 88Br. The International Atomic Energy Agency (IAEA) publishes eight-group parameters for several actinides; for thermal fission of U-235 they are:
Besides hemorrhagic stroke, myocardial infarction, coronary vasospasm, and sudden death have also rarely been reported with sympathomimetic ephedra compounds like pseudoephedrine and ephedrine. A 2005 meta-analysis found that pseudoephedrine at recommended doses had no meaningful effect on systolic or diastolic blood pressure in healthy individuals or people with controlled hypertension. Systolic blood pressure was found to slightly increase by 0.99 mm Hg on average and heart rate was found to slightly increase by 2.83 bpm on average. Conversely, there was no significant influence on diastolic blood pressure, which increased by 0.63 mg Hg. In people with controlled hypertension, systolic hypertension increased by a similar degree of 1.20 mm Hg. Immediate-release preparations, higher doses, being male, and shorter duration of use were all associated with greater cardiovascular effects. A small subset of individuals with autonomic instability, perhaps in turn resulting in greater adrenergic receptor sensitivity, may be substantially more sensitive to the cardiovascular effects of sympathomimetics. Subsequent to the 2005 meta-analysis, a 2015 systematic review and a 2018 meta-analysis found that pseudoephedrine at high doses (>170 mg) could increase heart rate and physical performance with larger effect sizes than lower doses. A 2007 Cochrane review assessed the side effects of short-term use of pseudoephedrine at recommended doses as a nasal decongestant.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.